Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New imaging method shows early in treatment if brain cancer therapy is effective

01.11.2005


Diffusion MRI is good early predictor of whether cancer will progress



A special type of MRI scan that measures the movement of water molecules through the brain can help doctors determine halfway through treatment whether it will successfully shrink the tumor or a patient’s cancer will continue to grow, a new study shows. The test identifies after only three weeks of treatment – more than two months earlier than traditional tests -- who is responding to the chemotherapy or radiation.

Researchers at the University of Michigan Comprehensive Cancer Center developed the assessment, which they call a functional diffusion map. They used a magnetic resonance imaging scan that tracks the diffusion, or movement, of water through the brain and mapped the changes in diffusion from the start of therapy to three weeks later. The tumor cells restrict the movement of water, so as those cells die, water diffusion changes.


In the study of 34 people with a type of brain tumor called high grade glioma, the researchers found that they could predict after three weeks, based on the functional diffusion map, which cancers would respond to the treatment and which cancers would continue to grow. These predictions corresponded to a significant difference in how long the patients lived.

Results of the study appear the week of Oct. 31 in the early online edition of the Proceedings of the National Academy of Sciences.

High grade gliomas have a high mortality rate, with people surviving only an average of 12 months after diagnosis. Typically, patients receive six to seven weeks of treatment, followed by a traditional MRI scan six weeks after completing therapy to determine if the tumor shrank. If the cancer did not respond to the treatment, a new approach may be tried.

"An early measure of tumor response such as this functional diffusion map could help doctors identify during the course of treatment who might benefit from a second-line therapy, sparing patients from a grueling treatment regimen that’s not working," says senior study author Brian Ross, Ph.D., professor of radiology and biological chemistry at the U-M Medical School and co-director of the Molecular Imaging Program at the U-M Comprehensive Cancer Center. "Just as importantly, this finding opens up the opportunity to study not only if treatment is unsuccessful, but where in the tumor it is not succeeding. If this is the case, we can use our sophisticated radiation planning techniques to target higher radiation doses to the regions that are not responding," says study author Theodore Lawrence, M.D., Ph.D., Isadore Lampe Professor and Chair of Radiation Oncology at the U-M Medical School.

In the study, 34 participants with late-stage diffuse high grade glioma, a type of brain tumor, underwent diffusion MRI before beginning a new treatment involving chemotherapy, radiation therapy or a combination. Three weeks later, they had another diffusion MRI. Eight to ten weeks after that, the participants underwent standard MRI to determine whether their tumor responded to the therapy.

At three weeks into treatment – more than two months before the final MRI scan – researchers could identify which patients would have a response to therapy over those with progressive disease. This corresponded to patients’ survival, with those classified as having progressive disease living an average 8.2 months while those with a response to treatment lived an average 18.2 months.

In addition, the time until the cancer began to progress was later in the group classified at three weeks by the functional diffusion map as having a partial response or stable disease, 7.3 months compared to 4.3 months for those identified as having progressive disease.

The researchers also looked at standard predictive factors of whether a patient is likely to do well on a therapy – factors such as age, tumor location and tumor size – but found the functional diffusion map was the only accurate predictor of overall survival.

"When the median survival for this type of cancer is less than 52 weeks, waiting an extra 10 weeks to know if treatment is working is a significant amount of time. We hope that functional diffusion mapping will eventually allow oncologists to manage each patient’s treatment based on real time evaluation of cellular response to therapy," says study author Suresh Mukherji, M.D., professor of radiology and otolaryngology and division director of neuroradiology at the U-M Medical School.

The researchers believe the test may be useful for other types of cancer, including breast, head and neck, rectal, prostate and liver. The functional diffusion map is not yet available for routine use in clinic.

Additional U-M study authors are Daniel Hamstra, M.D., a resident in radiation oncology; Thomas Chenevert, Ph.D., professor of radiology; Bradford Moffat, Ph.D., assistant professor of radiology; Timothy Johnson, Ph.D., adjunct assistant professor and assistant research scientist in biostatistics; Charles Meyer, Ph.D., professor of radiology; Douglas Quint, M.D., professor of radiology; Stephen Gebarski, M.D., professor of radiology; Xiaoying Fan, a research technician in radiology; Christina Tsien, M.D., assistant professor in radiation oncology; Larry Junck, M.D., professor of neurology; and Alnawaz Rehemtulla, Ph.D., associate professor of radiation oncology and radiology.

Funding for the study was from the National Cancer Institute and the Charles A. Dana Foundation.

The University of Michigan holds a patent on this MRI diffusion technology and has licensed the commercialization rights to Molecular Therapeutics of Ann Arbor, in which Ross and Rehemtulla have a financial interest. A diffusion MRI can be performed on a standard MRI machine using a special workstation to compute the diffusion map. A workstation is being developed by Cedara Software Corp. of Ontario, Canada. Ross, Rehemtulla and Chenevert, as inventors of this technology, would stand to benefit financially from any commercial products.

Nicole Fawcett | EurekAlert!
Further information:
http://www.cancer.med.umich.edu/learn/brain.htm
http://www.umich.edu

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Error-free into the Quantum Computer Age

A study carried out by an international team of researchers and published in the journal Physical Review X shows that ion-trap technologies available today are suitable for building large-scale quantum computers. The scientists introduce trapped-ion quantum error correction protocols that detect and correct processing errors.

In order to reach their full potential, today’s quantum computer prototypes have to meet specific criteria: First, they have to be made bigger, which means...

Im Focus: Search for planets with Carmenes successful

German and Spanish researchers plan, build and use modern spectrograph

Since 2016, German and Spanish researchers, among them scientists from the University of Göttingen, have been hunting for exoplanets with the “Carmenes”...

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

The body's street sweepers

18.12.2017 | Life Sciences

Fast flowing heat in layered material heterostructures

18.12.2017 | Materials Sciences

Life on the edge prepares plants for climate change

18.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>